FDA: Potential for opioids to be in Novartis OTC products in mix-up
This article was originally published in Scrip
The consumer-level recall Novartis issued for its over-the-counter (OTC) medicines Excedrin, NoDoz, Bufferin and Gas-X could be much more dangerous than the company disclosed in an 8 January weekend statement, with US regulators revealing that there is the potential that prescription opioids, such as Endo Pharmaceuticals' Opana ER (oxymorphone hydrochloride extended-release) and Percocet (oxycodone hydrochloride and acetaminophen), could have ended up in the bottles of the OTC drugs.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.